To evaluate the therapeutic impact of TERT-targeting immunotherapy in a more relevant setting, NOG mice were i.v. injected with 2.5×106 ALL-CM cells and tumour progression was weekly assessed by enumerating the frequency of circulating hCD19+ cells by flow cytometry, as previously described [43, 44]. The gene discussed is TERT; the disease is neoplasm.